Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Mihaela, Plesescu"'
Autor:
Suguru Kato, Swapan Chowdhury, Jayaprakasam Bolleddula, Mihaela Plesescu, Yoshinari Miyata, Abhi Shah, Xiaochun Zhu
Publikováno v:
Drug Metabolism and Disposition. 48:934-943
The PXB-mouse is potentially a useful in vivo model to predict human hepatic metabolism and clearance. Four model compounds, [14C]desloratadine, [3H]mianserin, cyproheptadine, and [3H]carbazeran, all reported with disproportionate human metabolites,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ced06eca08636d58fdba47f17d4f460
https://doi.org/10.1124/dmd.120.000128
https://doi.org/10.1124/dmd.120.000128
Autor:
Michael J. Hanley, Cindy Q. Xia, Swapan Chowdhury, Karthik Venkatakrishnan, Sandeepraj Pusalkar, Mihaela Plesescu, Xiaoquan Zhang, Neeraj Gupta, Jing-Tao Wu
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:803-814
This metabolite profiling and identification analysis (part of a phase I absorption, distribution, metabolism, and excretion study) aimed to define biotransformation pathways and evaluate associated inter-individual variability in four patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83cd8661aaa3fe7553c4d003a0f34d61
https://doi.org/10.1007/s00280-018-3671-z
https://doi.org/10.1007/s00280-018-3671-z
Autor:
Karthik Venkatakrishnan, Michael J. Hanley, Sandeepraj Pusalkar, Neeraj Gupta, Steven Zhang, Mihaela Plesescu, Xiaoquan Zhang, Bingxia Wang, Dale R. Shepard, Swapan Chowdhury, Cindy Q. Xia
Publikováno v:
Investigational New Drugs. 36:407-415
Summary This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. In Part A of the study, patients received a single 4.1 mg oral solution dose of [14C]-ix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f8e12a5907ce192f618e42bef8eb5de
https://doi.org/10.1007/s10637-017-0509-1
https://doi.org/10.1007/s10637-017-0509-1
Autor:
Yuexian Li, Mingxiang Liao, Miao Y. Guan, Jiyeon Woo, Johnny J. Yang, Shimoga Prakash, Jessica M. Chmielecki, Bei-Ching Chuang, Cindy Q. Xia, Mihaela Plesescu
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 26:551-555
The design, synthesis, in vitro inhibitory potency, and pharmacokinetic (PK) profiles of Ko143 analogs are described. Compared to commonly used Ko143, the new breast cancer resistance protein (BCRP) inhibitor (compound A) showed the same potency and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::470e947839261c321d1888e109064ff4
https://doi.org/10.1016/j.bmcl.2015.11.077
https://doi.org/10.1016/j.bmcl.2015.11.077
Autor:
Sandeepraj, Pusalkar, Mihaela, Plesescu, Neeraj, Gupta, Michael, Hanley, Karthik, Venkatakrishnan, Jing-Tao, Wu, Cindy, Xia, Xiaoquan, Zhang, Swapan, Chowdhury
Publikováno v:
Cancer chemotherapy and pharmacology. 82(5)
This metabolite profiling and identification analysis (part of a phase I absorption, distribution, metabolism, and excretion study) aimed to define biotransformation pathways and evaluate associated inter-individual variability in four patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9febe64fd7b6fa4ae4e8bd72c59420c3
https://pubmed.ncbi.nlm.nih.gov/30128949
https://pubmed.ncbi.nlm.nih.gov/30128949
Publikováno v:
International Journal of Cancer and Clinical Research. 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55347fd7ecdb84f217a87e61a03a39b3
https://doi.org/10.23937/2378-3419/1410082
https://doi.org/10.23937/2378-3419/1410082
Autor:
Neeraj, Gupta, Steven, Zhang, Sandeepraj, Pusalkar, Mihaela, Plesescu, Swapan, Chowdhury, Michael J, Hanley, Bingxia, Wang, Cindy, Xia, Xiaoquan, Zhang, Karthik, Venkatakrishnan, Dale R, Shepard
Publikováno v:
Investigational New Drugs
Summary This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. In Part A of the study, patients received a single 4.1 mg oral solution dose of [14C]-ix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f3cdf5932f53849f90734b827c3a1e3
https://pubmed.ncbi.nlm.nih.gov/28932928
https://pubmed.ncbi.nlm.nih.gov/28932928
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 57:574-578
[(13) CD3 ]-TAK-459 (1A), an HSP90 inhibitor, was synthesized from [(13) CD3 ]-sodium methoxide in three steps in an overall yield of 29%. The key intermediate [(13) CD3 ]-2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine was synthesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::071e85a4012a06ba62f11a78c0d1870b
https://doi.org/10.1002/jlcr.3217
https://doi.org/10.1002/jlcr.3217
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 56:475-479
L-MTP-PE (1), an immunomodulator and its metabolite MDP (4) were synthesized from labeled l-alanine and its protected derivative, respectively. The key intermediate product for the labeled L-MTP-PE synthesis, [(13) C3 ,D4 ]-alanyl-cephalin (2A), was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1556412802b0ff8b812cc7d3bc5618bd
https://doi.org/10.1002/jlcr.3078
https://doi.org/10.1002/jlcr.3078
Publikováno v:
Tetrahedron Letters. 52:1807-1810
The synthesis of two isotopically labeled versions of an investigational NAE inhibitor (MLN4924) is reported. 14 C-MLN4924 was synthesized from 14 C-thiourea in eight steps. D 8 -MLN4924 was prepared from D 9 -3-phenylpropanoic acid in seven steps.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17fdfc8dfed3a8460003f57f28be1de2
https://doi.org/10.1016/j.tetlet.2011.02.033
https://doi.org/10.1016/j.tetlet.2011.02.033